Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 7Sarcoma 1Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Cytarabine 116Cyclophosphamide 104venetoclax 89fludarabine 85Azacitidine 81fludarabine phosphate 70Rituximab 59Filgrastim 44Peripheral Blood Stem Cell Transplantation 39Methotrexate 39Dexamethasone 35Decitabine 35Busulfan 32Etoposide 31Tacrolimus 30Mycophenolic Acid 29Granulocyte Colony-Stimulating Factor 28Lenalidomide 27Whole-Body Irradiation 26Idarubicin 26Vincristine 25Melphalan 24Cyclosporine 24Clofarabine 24Mitoxantrone 22Bortezomib 21Alemtuzumab 21ibrutinib 19ruxolitinib 17aldesleukin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × carmustine, poliferprosan 20 drug combination × Other hematologic neoplasm × Clear all
NCT00005803 2020-01-29

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Completed
76 enrolled 11 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡